YORK medical device company Tissue Regenix is targeting an £83 million market with its first commercial launch in the US.
The York Science Park company is to start shipping its DermaPure products next week after year developing the skin scaffolding process, which removes DNA and cells from grafts to enable wound healing.
In addition to the launch of DermaPure, the Group also announces that it has continued to expand its distribution network around the country and has a network of more than 60 reps covering 80 per cent of the US.
Antony Odell, chief executive of Tissue Regenix Group said: “Tissue Regenix has managed to establish the US organisation and launch its first product less than 18 months after forming our North American subsidiary company, and we are now fully established and ready to demonstrate the commercial power of dCELL.
“We look forward to continuing to progress the commercialisation of our unique technology.”
Tissue Regenix has also signed an exclusive government supplier partnership with TASSMA for the distribution of DermaPure.
TASSMA provides business development services to medical device and equipment manufacturers seeking to rapidly grow their federal government market share. The partnership with TASSMA will allow Tissue Regenix to immediately target the Department of Veteran’s Affairs Healthcare System and the numerous branches of the US military.
Greg Bila, president of Tissue Regenix Wound Care Inc. said: “Commercial production and distribution of the DermaPure is a significant step forward for Tissue Regenix.
“This paves the way for the development of other human tissue based medical treatments.
“DermaPure is initially being targeted at acute care patients with diabetic foot ulcers, a condition which affects around 600,000 people in the US each year, and patients with venous leg ulcers, which currently affect around 2.5 million people in the US.
“We see this as a large market that is in need of medical innovation, which is exactly what DermaPure provides.”